Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 114400.0
(-4.75%)
KRW 114400.0
(-4.75%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 109.56 Billion KRW | -13.83% |
| 2022 | 127.15 Billion KRW | 35.78% |
| 2021 | 93.64 Billion KRW | 57.7% |
| 2020 | 59.38 Billion KRW | -11.31% |
| 2019 | 66.95 Billion KRW | 20.87% |
| 2018 | 55.39 Billion KRW | 52.24% |
| 2017 | 36.38 Billion KRW | 6.71% |
| 2016 | 34.09 Billion KRW | 13.92% |
| 2015 | 29.93 Billion KRW | 12.75% |
| 2014 | 26.54 Billion KRW | -26.56% |
| 2013 | 36.14 Billion KRW | 1.98% |
| 2012 | 35.44 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 134.91 Billion KRW | 19.02% |
| 2024 Q1 | 113.36 Billion KRW | 3.47% |
| 2023 Q2 | 135.65 Billion KRW | 2.63% |
| 2023 Q1 | 132.18 Billion KRW | 3.56% |
| 2023 FY | 109.56 Billion KRW | -13.83% |
| 2023 Q4 | 109.56 Billion KRW | -9.79% |
| 2023 Q3 | 121.44 Billion KRW | -10.47% |
| 2022 Q4 | 127.63 Billion KRW | 3.31% |
| 2022 FY | 127.15 Billion KRW | 35.78% |
| 2022 Q3 | 123.53 Billion KRW | 7.4% |
| 2022 Q2 | 115.03 Billion KRW | 2.34% |
| 2022 Q1 | 112.39 Billion KRW | 20.02% |
| 2021 Q3 | 92.03 Billion KRW | 0.07% |
| 2021 Q4 | 93.64 Billion KRW | 1.75% |
| 2021 FY | 93.64 Billion KRW | 57.7% |
| 2021 Q2 | 91.97 Billion KRW | 0.12% |
| 2021 Q1 | 91.86 Billion KRW | 54.69% |
| 2020 Q1 | 67.06 Billion KRW | 0.16% |
| 2020 Q3 | 58.24 Billion KRW | -7.37% |
| 2020 Q4 | 59.38 Billion KRW | 1.95% |
| 2020 Q2 | 62.88 Billion KRW | -6.24% |
| 2020 FY | 59.38 Billion KRW | -11.31% |
| 2019 Q3 | 59.85 Billion KRW | 4.05% |
| 2019 Q2 | 57.52 Billion KRW | 2.26% |
| 2019 Q1 | 56.25 Billion KRW | 1.55% |
| 2019 FY | 66.95 Billion KRW | 20.87% |
| 2019 Q4 | 66.95 Billion KRW | 11.86% |
| 2018 Q2 | 26.8 Billion KRW | -33.02% |
| 2018 Q1 | 40.01 Billion KRW | 9.97% |
| 2018 Q4 | 55.39 Billion KRW | 122.51% |
| 2018 FY | 55.39 Billion KRW | 52.24% |
| 2018 Q3 | 24.89 Billion KRW | -7.12% |
| 2017 FY | 36.38 Billion KRW | 6.71% |
| 2017 Q2 | 26.36 Billion KRW | -4.78% |
| 2017 Q3 | 25.47 Billion KRW | -3.38% |
| 2017 Q4 | 36.38 Billion KRW | 42.82% |
| 2017 Q1 | 27.69 Billion KRW | 5.92% |
| 2016 Q3 | 22.15 Billion KRW | 0.37% |
| 2016 FY | 34.09 Billion KRW | 13.92% |
| 2016 Q1 | 22.32 Billion KRW | 2.81% |
| 2016 Q4 | 26.14 Billion KRW | 18.0% |
| 2016 Q2 | 22.07 Billion KRW | -1.11% |
| 2015 Q1 | 22.76 Billion KRW | -14.25% |
| 2015 Q4 | 21.71 Billion KRW | 0.39% |
| 2015 Q3 | 21.62 Billion KRW | 5.33% |
| 2015 Q2 | 20.53 Billion KRW | -9.79% |
| 2015 FY | 29.93 Billion KRW | 12.75% |
| 2014 Q1 | 37.24 Billion KRW | 3.03% |
| 2014 FY | 26.54 Billion KRW | -26.56% |
| 2014 Q3 | 25.78 Billion KRW | 4.06% |
| 2014 Q2 | 24.78 Billion KRW | -33.46% |
| 2014 Q4 | 26.54 Billion KRW | 2.95% |
| 2013 Q1 | 33.29 Billion KRW | -6.06% |
| 2013 Q2 | 38.93 Billion KRW | 16.93% |
| 2013 FY | 36.14 Billion KRW | 1.98% |
| 2013 Q3 | 39.53 Billion KRW | 1.54% |
| 2013 Q4 | 36.14 Billion KRW | -8.56% |
| 2012 FY | 35.44 Billion KRW | 0.0% |
| 2012 Q4 | 35.44 Billion KRW | 131.06% |
| 2012 Q3 | 15.33 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 7.52 Billion KRW | -1356.793% |
| ST Pharm Co.,Ltd. | 299.92 Billion KRW | 63.47% |
| ABL Bio Inc. | 86.06 Billion KRW | -27.301% |
| Cellid, Co., Ltd. | 23.42 Billion KRW | -367.673% |